Introduction {#s1}
============

Atrial fibrillation (AF) is associated with a fivefold increase in stroke risk.[@R1] Strokes associated with AF have a poorer prognosis compared with non-AF stroke.[@R2] Evidence-based guidelines for stroke prevention in AF recommend anticoagulant (AC) therapy for patients with additional stroke risk factors,[@R3] but AC therapy is underused in eligible patients.[@R6] Furthermore, data from registries suggest that AC therapy is underused in patients at high stroke risk and potentially overused in those at low stroke risk.[@R7]

The most recent European and North American guidelines for the management of AF incorporate recommendations on using non-vitamin K antagonist oral ACs (NOACs) as an alternative to vitamin K antagonists (VKAs).[@R3] In the present study, the evolving patterns of antithrombotic therapy were investigated using data from a large, prospective, global cohort study of patients with newly diagnosed non-valvular AF in different countries, geographic regions, care settings, and in patients at different levels of stroke and bleeding risks.

Methods {#s2}
=======

Study design and participants {#s2a}
-----------------------------

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing, prospective, observational, worldwide study of adults with recently diagnosed non-valvular AF from 1215 sites in 35 countries. The study design has been described previously.[@R12] Briefly, men and women aged ≥18 years with non-valvular AF diagnosed according to standard local procedures within the previous 6 weeks and ≥1 additional risk factor for stroke as judged by the investigator are eligible. These risk factors are not prespecified in the protocol, nor are they limited to the components of existing risk stratification schemes. Patients with a transient reversible cause of AF and those for whom follow-up is not envisaged or possible are excluded. Enrolment takes place in five independent, sequential cohorts. To minimise recruitment bias, investigator sites were selected randomly from representative care settings in each participating country and consecutive patients were enrolled. Sample size calculations are based on the 95% confidence intervals for estimates of each of the registry endpoints.[@R12]

This paper reports cross-sectional data at baseline including treatment patterns before and after the introduction of NOACs, for cohorts 1--4 (cohort 1: March 2010 to October 2011; cohort 2: August 2011 to June 2013; cohort 3: April 2013 to October 2014; cohort 4: March 2014 to July 2015), and has been written according to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement.

Data collection {#s2b}
---------------

The electronic case report form (eCRF) was designed by Dendrite Clinical Systems Ltd (Henley-on-Thames, UK). Oversight of operations and data management was conducted by the sponsor and coordinating centre (Thrombosis Research Institute---TRI, London, UK), with support from Quintiles (Durham, North Carolina, USA), The University of Birmingham Department of Primary Care Clinical Sciences (Birmingham, UK), Thrombosis Research Group---Brigham and Women\'s Hospital (Boston, Massachusetts, USA), and AIXIAL (Paris, France). The GARFIELD-AF protocol requires source data verification of 20% of eCRFs, an electronic audit trail for all data modifications, and additional audit of critical variables.[@R12] Data for the analysis in this report were extracted from the study database on 3 August 2015.

Definitions {#s2c}
-----------

The term AC includes VKAs and NOACs*.* The term NOAC includes oral direct factor Xa inhibitors (FXaIs) and oral direct thrombin inhibitors (DTIs)*.* Vascular disease was defined as peripheral artery disease and/or coronary artery disease (CAD) with a history of acute coronary syndromes. Hypertension was defined as a documented history of hypertension or blood pressure \>140/90 mm Hg. Chronic kidney disease (CKD) was classified according to the National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines:[@R13] moderate-to-severe includes stages III to V; none or mild includes all other patients. Congestive heart failure (CHF) was defined as a history of CHF for patients in cohorts C1 and C2; from C3 onwards there was a protocol amendment and in these cohorts, CHF consists of current or prior history of CHF.

Ethics statement {#s2d}
----------------

Independent ethics committee and hospital-based institutional review board approvals were obtained, as necessary, for the registry protocol. The registry is being performed in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on Harmonisation--Good Pharmacoepidemiological and Clinical Practice guidelines. All patients gave written informed consent to participate.

Statistical analysis {#s2e}
--------------------

The analysis provides descriptive statistics to summarise data patterns. Continuous variables are expressed as mean±SD and categorical variables as frequency and percentage. Treatment patterns were analysed by cohort, by cohort and CHA~2~DS~2~-VASc (cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65--74 and sex category (female)) score,[@R14] and by cohort and 'modified' HAS-BLED (hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile international normalised ratios, elderly (\>65), drugs/alcohol concomitantly (1 point each)) score[@R15] (fluctuations in international normalised ratios were not collected). The risk scores were calculated retrospectively. NOAC use (relative to VKA) was analysed according to patient characteristics, comorbidities, and cohort. Patients in cohorts C2, C3, and C4 using VKA or NOACs were included in the analysis. We removed patients in C1, since NOACs were not globally available during this time period. Adjusted odds ratios were estimated using a logistic model based on the following variables: gender, age group, race, smoking, CHF, hypertension, diabetes, CAD, vascular disease, dementia, moderate-to-severe CKD, non-steroidal anti-inflammatory drug (NSAID) usage, history of bleeding, previous stroke/transient ischaemic attack (TIA)/systemic embolism (SE), and cohort. Multiple Imputation by Chained Equations (MICE) was used to fill in missing values, creating five complete datasets.[@R16] [@R17] First-degree interaction between baseline characteristics and time (cohort) or between comorbidities and time (cohort) were tested using likelihood ratio tests. Only significant interactions were included in the final model.

Both SAS V.9.4 (SAS Institute Inc, Cary, North Carolina, USA) and Stata Statistical Software: Release 14 (StataCorp, College Station, Texas, USA) were used for the data analysis.

Results {#s3}
=======

Study population {#s3a}
----------------

Between March 2010 and July 2015, 39 670 patients were enrolled in four sequential cohorts: C1 (2010--2011), n=5500; C2 (2011--2013), n=11 662; C3 (2013--2014), n=11 462; C4 (2014--2015), n=11 046. Baseline characteristics across the four cohorts were similar, although C3 and C4 had a slightly lower prevalence of prior stroke/TIA ([table 1](#HEARTJNL2016309832TB1){ref-type="table"}).

###### 

Baseline characteristics of patients in cohorts 1 to 4

  ----------------------------------------------------------------------------------------------------------------------
  Variable                             Cohort 1\          Cohort 2\            Cohort 3\            Cohort 4\
                                       2010--2011\        2011--2013\          2013--2014\          2014--2015\
                                       (n=5500)           (n=11 662)           (n=11 462)           (n=11 046)
  ------------------------------------ ------------------ -------------------- -------------------- --------------------
  Female, n/N (%)                      2402/5500 (43.7)   5116/11 662 (43.9)   5191/11 462 (45.3)   4870/11 046 (44.1)

  Age at diagnosis, years, mean (SD)   69.8 (11.5)        69.8 (11.4)          69.6 (11.4)^a^       69.6 (11.7)

  Ethnicity, n/N (%)                                                                                

   Caucasian/Hispanic/Latino           3691/5500 (67.1)   8647/11 662 (74.1)   7896/11 462 (68.9)   7050/11 046 (63.8)

   Asian                               1589/5500 (28.8)   2392/11 662 (20.5)   3175/11 462 (27.7)   3574/11 046 (32.4)

   Other                               68/5500 (1.2)      244/11 662 (2.1)     147/11 462 (1.3)     239/11 046 (2.2)

   Unwilling to declare                152/5500 (2.8)     379/11 662 (3.2)     244/11 462 (2.1)     183/11 046 (1.7)

  Medical history, n/N (%)                                                                          

   CHF                                 1026/5498 (18.7)   2506/11 662 (21.5)   2206/11 462 (19.2)   2128/11 046 (19.3)

   CAD                                 1059/5498 (19.3)   2357/11 662 (20.2)   2495/11 462 (21.8)   2428/11 046 (22.0)

   ACS                                 553/5498 (10.1)    1061/11 659 (9.1)    1258/11 257 (11.2)   1281/10 884 (11.8)

   Vascular disease                    847/5498 (15.4)    1653/11 662 (14.2)   1828/11 462 (15.9)   1789/11 046 (16.2)

   Systemic embolism                   35/5498 (0.6)      74/11 652 (0.6)      85/11 383 (0.7)      78/10 981 (0.7)

   Stroke/TIA                          727/5498 (13.2)    1459/11 662 (12.5)   1236/11 462 (10.8)   1219/11 046 (11.0)

   Bleeding                            172/5498 (3.1)     325/11 651 (2.8)     283/11 400 (2.5)     262/10 995 (2.4)

   History of hypertension             4224/5498 (76.8)   9172/11 662 (78.6)   8761/11 419 (76.7)   8224/11 004 (74.7)

   Diabetes mellitus                   1215/5498 (22.1)   2535/11 662 (21.7)   2457/11 462 (21.4)   2443/11 046 (22.1)

   Moderate-to-severe CKD\*            495/5497 (9.0)     1265/11 662 (10.8)   1209/11 462 (10.5)   1104/11 045 (10.0)

  Risk scores                                                                                       

   CHA~2~DS~2~-VASc, median (Q1--Q3)   3 (2--4)^b^        3 (2--4)^c^          3 (2--4)^d^          3 (2--4)^e^

   CHA~2~DS~2~-VASc, 0--1, n/N (%)     815/5406 (15.1)    1531/11 293 (13.6)   1666/11 252 (14.8)   1700/10 830 (15.7)

   HAS-BLED, median (Q1--Q3)†          1 (1--2)^f^        1 (1--2)^g^          1 (1--2)^h^          1 (1--2)^i^

   HAS-BLED, 0--2, n/N (%)†            3109/3561 (87.3)   6321/7302 (86.6)     7650/8584 (89.1)     7824/8654 (90.4)
  ----------------------------------------------------------------------------------------------------------------------

^a^1 patient missing; ^b^94 patients missing; ^c^369 patients missing; ^d^210 patients missing; ^e^216 patients missing; ^f^1939 patients missing; ^g^4360 patients missing; ^h^2878 patients missing; ^i^2392 patients missing.

ACS, acute coronary syndrome; CAD, coronary artery disease; CHA~2~DS~2~-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65--74 and sex category (female); CHF, congestive heart failure; CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative; TIA, transient ischaemic attack.

\*Includes NKF KDOQI stages III--V.

†'modified' HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (\>65), drugs/alcohol concomitantly (1 point each).

Antithrombotic therapy use by cohort {#s3b}
------------------------------------

[Figure 1](#HEARTJNL2016309832F1){ref-type="fig"} shows the prescribing patterns at diagnosis of AF in all four cohorts. The proportion of patients on AC therapy at diagnosis, with or without an antiplatelet (AP) agent, increased from C1 to C4. This rise was due to increasing use of NOACs, with or without AP, and was greater for FXaIs than for DTI. At the same time, there was a decline in the use of VKA, with or without AP, as well as AP therapy alone, while the proportion of patients not receiving antithrombotic therapy remained unchanged. [Table 2](#HEARTJNL2016309832TB2){ref-type="table"} shows the baseline characteristics for all patients by treatment group. Patients receiving no treatment were generally younger and healthier, with a lower incidence of comorbidities, and had lower CHA~2~DS~2~-VASc and HAS-BLED scores.

###### 

Baseline characteristics of patients in cohort 1 to cohort 4 by antithrombotic treatment type

  Variable                             None                AP alone            AC+AP or AP alone   AC+AP               NOAC+AP             VKA+AP              AC±AP               NOAC alone          VKA alone
  ------------------------------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  N                                    4802                8714                14 309              5595                1656                3939                25 680              7244                12 841
  Female, n (%)                        2135 (44.5)         3774 (43.3)         5957 (41.6)         2183 (39.0)         656 (39.6)          1527 (38.8)         11 449 (44.6)       3267 (45.1)         5999 (46.7)
  Age at diagnosis, years, mean (SD)   66.8 (13.5)         68.7 (12.1)^a^      69.4 (11.5)^a^      70.5 (10.4)         71.2 (10.5)         70.3 (10.3)         70.6 (10.7)         70.7 (10.9)         70.6 (10.8)
  Medical history, n (%)                                                                                                                                                                               
   CAD                                 494 (10.3)^b^       2834 (32.5)         5139 (35.9)         2305 (41.2)         708 (42.8)          1597 (40.5)         4883 (19.0)         857 (11.8)          1721 (13.4)
   Vascular disease                    358 (7.5)^b^        1865 (21.4)         3628 (25.4)         1763 (31.5)         532 (32.1)          1231 (31.3)         3810 (14.8)         682 (9.4)           1365 (10.6)
   Systemic embolism                   14 (0.3)^b^         34 (0.4)            96 (0.7)            62 (1.1)            19 (1.2)            43 (1.1)            216 (0.8)           39 (0.5)            115 (0.9)
   Stroke                              202 (4.2)^b^        665 (7.7)           1316 (9.2)          651 (11.7)          178 (10.8)          473 (12.0)          2162 (8.4)          508 (7.0)           1003 (7.8)
   Bleeding                            221 (4.6)^b^        301 (3.5)           438 (3.1)           137 (2.5)           37 (2.2)            100 (2.5)           492 (1.9)           150 (2.1)           205 (1.6)
   Hypertension                        3439 (71.6)^b^      7007 (80.4)         11 787 (82.4)       4780 (85.4)         1403 (84.7)         3377 (85.7)         21 345 (83.1)       5831 (80.5)         10 734 (83.6)
   Diabetes mellitus                   831 (17.3)^b^       1816 (20.8)         3533 (24.7)         1717 (30.7)         492 (29.7)          1225 (31.1)         5884 (22.9)         1354 (18.7)         2813 (21.9)
   Moderate-to-severe CKD\*            371 (7.7)^b^        826 (9.5)^a^        1581 (11.0)^a^      755 (13.5)          208 (12.6)          547 (13.9)          2818 (11.0)^a^      677 (9.3)           1386 (10.8)^a^
  Risk scores                                                                                                                                                                                          
   CHA~2~DS~2~-VASc, median (Q1--Q3)   3.0 (1.0--4.0)^c^   3.0 (2.0--4.0)^d^   3.0 (2.0--4.0)^e^   4.0 (3.0--5.0)^f^   4.0 (3.0--5.0)^g^   4.0 (3.0--5.0)^h^   3.0 (2.0--4.0)^i^   3.0 (2.0--4.0)^j^   3.0 (2.0--4.0)^k^
   CHA~2~DS~2~-VASc, 0--1, n (%)       1212 (26.5)         1457 (17.1)         1902 (13.5)         445 (8.1)           137 (8.3)           308 (7.9)           2988 (11.9)         1079 (15.1)         1464 (11.7)
   HAS-BLED, median (Q1--Q3)†          1.0 (0.0--1.0)^l^   2.0 (1.0--2.0)^m^   2.0 (1.0--2.0)^n^   2.0 (2.0--3.0)^o^   2.0 (2.0--2.0)^p^   2.0 (1.0--3.0)^q^   1.0 (1.0--2.0)^r^   1.0 (1.0--2.0)^s^   1.0 (1.0--2.0)^t^
   HAS-BLED, 0--2, n (%)†              2984 (94.2)         4742 (80.0)         7718 (78.0)         2976 (75.0)         911 (76.2)          2065 (74.5)         16 865 (90.4)       5271 (95.0)         8618 (94.4)

^a^1 patient missing; ^b^2 patients missing; ^c^225 patients missing; ^d^175 patients missing; ^e^244 patients missing; ^f^69 patients missing; ^g^15 patients missing; ^h^54 patients missing; ^i^481 patients missing; ^j^116 patients missing; ^k^296 patients missing; ^l^1634 patients missing; ^m^2787 patients missing; ^n^4413 patients missing; ^o^1626 patients missing; ^p^460 patients missing; ^q^1166 patients missing; ^r^7032 patients missing; ^s^1697 patients missing; ^t^3709 patients missing.

AC, anticoagulant; AP, antiplatelet; CAD, coronary artery disease; CHA~2~DS~2~-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65--74 and sex category (female); CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.

\*Includes NKF KDOQI stages III--V.

†'modified' HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (\>65), drugs/alcohol concomitantly (1 point each).

![Antithrombotic treatment at diagnosis by cohort. The total population represented by n excludes unknowns. AP, antiplatelet; DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonist.](heartjnl-2016-309832f01){#HEARTJNL2016309832F1}

[Table 3](#HEARTJNL2016309832TB3){ref-type="table"} shows the baseline characteristics of patients on NOACs by cohort. Patients treated early after the introduction of NOACs (C1) were more likely than those in later cohorts to suffer from significant underlying disease such as CAD, vascular disease, CKD, and diabetes. Analysis of the baseline characteristics of 20 167 patients in the later cohorts (C2, C3, and C4) who were prescribed either VKA or NOACs found that NOAC use was more frequent than VKA use in men, patients of Asian ethnicity, the elderly, patients with dementia, those using NSAIDs, and current smokers ([table 4](#HEARTJNL2016309832TB4){ref-type="table"}). VKA use was more common in patients with cardiac, vascular, or renal comorbidities.

###### 

Baseline characteristics of patients on NOACs by cohort

  Variable                             Cohort 1 2010--2011   Cohort 2 2011--2013   Cohort 3 2013--2014   Cohort 4 2014--2015
  ------------------------------------ --------------------- --------------------- --------------------- ---------------------
  N                                    224                   1611                  3000                  4065
  Female, n (%)                        102 (45.5)            703 (43.6)            1351 (45.0)           1767 (43.5)
  Age at diagnosis, years, mean (SD)   70.9 (12.5)           70.5 (11.1)           70.8 (10.7)           70.9 (10.7)
  Medical history, n (%)                                                                                 
   CAD                                 62 (27.7)             254 (15.8)            518 (17.3)            731 (18.0)
   Vascular disease                    59 (26.3)             187 (11.6)            381 (12.7)            587 (14.4)
   Systemic embolism                   2 (0.9)               15 (0.9)              12 (0.4)              29 (0.7)
   Stroke                              19 (8.5)              163 (10.1)            190 (6.3)             314 (7.7)
   Bleeding                            13 (5.8)              32 (2.0)              56 (1.9)              86 (2.1)
   Hypertension                        175 (78.1)            1316 (81.7)           2464 (82.1)           3279 (80.7)
   Diabetes mellitus                   61 (27.2)             321 (19.9)            614 (20.5)            850 (20.9)
   Moderate-to-severe CKD\*            40 (17.9)             158 (9.8)             307 (10.2)            380 (9.3)
  Risk scores                                                                                            
   CHA~2~DS~2~-VASc, median (Q1--Q3)   4.0 (2.0--5.0)^a^     3.0 (2.0--4.0)^b^     3.0 (2.0--4.0)^c^     3.0 (2.0--4.0)^d^
   CHA~2~DS~2~-VASc, 0--1, n (%)       29 (13.0)             209 (13.2)            407 (13.8)            571 (14.2)
   HAS-BLED, median (Q1--Q3)†          2.0 (1.0--2.0)^e^     1.0 (1.0--2.0)^f^     1.0 (1.0--2.0)^g^     1.0 (1.0--2.0)^h^
   HAS-BLED, 0--2, n (%)†              130 (78.8)            956 (89.8)            2132 (92.2)           2964 (92.6)

^a^1 patient missing; ^b^32 patients missing; ^c^41 patients missing; ^d^57 patients missing; ^e^59 patients missing; ^f^547 patients missing; ^g^687 patients missing; ^h^864 patients missing.

CAD, coronary artery disease; CHA~2~DS~2~-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65--74 and sex category (female); CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant.

\*Includes NKF KDOQI stages III--V.

†'modified' HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (\>65), drugs/alcohol concomitantly (1 point each).

###### 

Use of NOACs in relation to baseline characteristics for patients on AC at baseline (n=20 167)

  Variable                                                        OR‡ (95% CI)
  --------------------------------------------------------------- ---------------------
  Gender                                                          
   Female                                                         1
   Male                                                           1.08 (1.01 to 1.15)
  Ethnicity                                                       
   Caucasian/Hispanic/Latino                                      1
   Asian                                                          1.28 (1.19 to 1.37)
   Other                                                          1.08 (0.87 to 1.35)
  Age, years                                                      
   65                                                             1
   65--80                                                         1.10 (1.02 to 1.18)
   80--85                                                         1.19 (1.08 to 1.32)
   \>85                                                           1.32 (1.16 to 1.50)
  Medical history\*                                               
   CHF                                                            0.94 (0.87 to 1.01)
   Hypertension (history or \>140/90 mm Hg)                       0.90 (0.83 to 0.97)
   Diabetes                                                       0.82 (0.77 to 0.88)
   CAD                                                            0.85 (0.77 to 0.94)
   Vascular disease                                               0.87 (0.79 to 0.97)
   Dementia                                                       1.46 (1.13 to 1.88)
   Moderate-to-severe CKD†                                        0.84 (0.76 to 0.92)
   NSAID usage                                                    1.27 (1.06 to 1.53)
   Bleeding                                                       1.19 (0.96 to 1.48)
  Smoking                                                         
   Never                                                          1
   Ex-smoker                                                      1.05 (0.98 to 1.13)
   Current smoker                                                 1.16 (1.05 to 1.29)
  Previous stroke/TIA/SE (reference: no previous stroke/TIA/SE)   
    In cohort 2 (2011--2013)                                      1.08 (0.91 to 1.28)
    In cohort 3 (2013--2014)                                      0.76 (0.65 to 0.89)
    In cohort 4 (2014--2015)                                      0.95 (0.82 to 1.10)
  Patients without stroke/TIA/SE                                  
    Cohort 2 (2011--2013)                                         1
    Cohort 3 (2013--2014)                                         2.33 (2.14 to 2.53)
    Cohort 4 (2014--2015)                                         3.82 (3.52 to 4.15)
  Patients with previous stroke/TIA/SE                            
    Cohort 2 (2011--2013)                                         1
    Cohort 3 (2013--2014)                                         1.64 (1.32 to 2.03)
    Cohort 4 (2014--2015)                                         3.37 (2.74 to 4.15)

\*Reference group is patients with no medical history.

†Includes NKF KDOQI stages III to V; none or mild (reference group) includes all other patients.

‡An OR \>1 implies that NOACs are more frequent than VKAs, while an OR \<1 means that VKAs are more frequent than NOACs. Only the interaction between cohort and stroke/TIA/SE was statistically significant (p=0.01).

AC, anticoagulant; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; NKF KDOQI, National Kidney Foundation\'s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin K antagonist.

Antithrombotic therapy use according to risk score {#s3c}
--------------------------------------------------

Use of antithrombotic therapy stratified by CHA~2~DS~2~-VASc score and cohort is shown in [figure 2](#HEARTJNL2016309832F2){ref-type="fig"}. Regardless of cohort, the proportion of patients on AC therapy increased with CHA~2~DS~2~-VASc score. Although the highest levels of anticoagulation were observed in patients with a CHA~2~DS~2~-VASc score ≥2, the increase in anticoagulation from C1 to C4 was greatest in patients with a score of 0. NOAC prescribing increased between C1 and C4 in all CHA~2~DS~2~-VASc score strata.

![Antithrombotic treatment at diagnosis by CHA~2~DS~2~-VASc score and cohort, for patients with a score of 0, 1, and ≥2. The total population represented by n excludes unknowns. Patients with missing CHA~2~DS~2~-VASc score: C1 94; C2 369; C3 210; C4 216. AP, antiplatelet; CHA~2~DS~2~-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65--74 and sex category (female); DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K antagonist.](heartjnl-2016-309832f02){#HEARTJNL2016309832F2}

Stratifying treatment by HAS-BLED score ([figure 3](#HEARTJNL2016309832F3){ref-type="fig"}), the proportion of patients on AC therapy decreased with increasing score, especially beyond a score of 2. In contrast, higher HAS-BLED scores were associated with a greater proportion of patients on AP therapy alone or in combination with an AC. As the HAS-BLED score increased, the proportion of patients on no treatment rose.

![Antithrombotic treatment at diagnosis by HAS-BLED score,\* for patients with a score of 0, 1, 2, and ≥3, in all cohorts combined. The total population represented by n excludes unknowns. Patients with missing HAS-BLED score: C1 1939; C2 4360; C3 2878; C4 2392. AP, antiplatelet; DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; \*'modified' HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (\>65), drugs/alcohol concomitantly (1 point each); VKA, vitamin K antagonist.](heartjnl-2016-309832f03){#HEARTJNL2016309832F3}

Discussion {#s4}
==========

Data from the GARFIELD-AF cohorts collected over the past 5 years show a pronounced change in the pattern of antithrombotic therapy prescribing in patients with newly diagnosed AF. The use of AC therapy has increased and exceeds 70% in the most recent cohort. This change is predominantly due to increasing use of NOACs. Thromboprophylaxis with AP and VKA therapies alone and in combination has declined.

This paradigm shift in prescribing practice has been driven in part by the availability of NOACs, but also the realisation that APs are barely effective compared with ACs. Evaluating the professional society guidelines published over the last 5 years (especially relating to AP therapy),[@R3] [@R4] [@R18] it is notable that the Japanese guidelines, for example, no longer recommend AP for stroke prevention in patients with AF. European Society of Cardiology and National Institute for Health and Care Excellence (NICE) guidelines also restrict the use of aspirin and other AP therapies for patients who refuse anticoagulation. American College of Cardiology/American Heart Association and Canadian guidelines have curtailed their recommendations on the use of these agents.[@R4] [@R21] [@R22]

Changes in AC therapy have occurred despite initial reluctance on the part of healthcare payers due to the greater cost of NOAC medication compared with VKA or AP therapy. However, the evidence suggests that long-term therapy with NOACs may be cost-effective compared with VKA treatment,[@R23] [@R24] primarily due to lower monitoring costs and reduced numbers of patients with strokes and SE.

CHA~2~DS~2~-VASc score analysis showed an increase in the use of NOAC therapy at all levels of risk, including those patients with a score of 0. While this may indicate some level of overtreatment, it should be noted that the patients with AF recruited into GARFIELD-AF were judged by their physician to have at least one additional risk factor for stroke. Patients may also have been prescribed ACs for transient purposes such as cardioversion or AF ablation. HAS-BLED score analysis found that AC prescribing diminished as bleeding risk increased, and a surprisingly high frequency of AP therapy alone or combined with ACs was still prescribed.

Notably, we have previously shown that there are no gender differences in the treatment patterns of patients (in C1 and C2).[@R25] Patients treated early after the introduction of NOACs (cohort C1) were more likely than those in later cohorts to suffer from significant underlying disease. Analysis of the later cohorts found that NOACs were more frequently used than VKAs in the elderly and in those with dementia or taking NSAIDs, perhaps because of their ease of use and the perceived lower bleeding risk. The preferential use of NOACs in patients of Asian ethnicity may have been an attempt to lower the incidence of intracranial haemorrhage. A higher frequency of patients with hypertension, CAD, and diabetes was prescribed VKAs, possibly combined with AP therapy, since experience with the combination of NOAC and AP is limited.[@R26] Patients with CKD were more likely to receive VKAs, presumably because of the moderate-to-high dependency of NOACs on renal elimination. It appears that, despite compelling evidence for the use of NOACs in secondary prevention,[@R27] prescribers remain relatively wary of NOAC thromboprophylaxis in patients with prior thromboembolic events, predominantly stroke.

The acceptance of AC therapy in AF among physicians is a positive step. However, there has been no decrease in the proportion of patients that receive no antithrombotic treatment, which remains at about 10% of the population. This population includes some patients at high thromboembolic risk, with low HAS-BLED scores, for whom anticoagulation would seem to be appropriate.

GARFIELD-AF provides a unique picture of prescribing at the end of the VKA-only era, showing the global increase in NOAC prescribing. Our findings are strengthened by protocol-mandated source data verification of 20% of eCRFs and central monitoring, ensuring high data quality. A limitation of this study is that only global patterns of antithrombotic therapy were investigated. Regional differences in prescribing trends were not taken into account, nor was the rate of NOAC approvals across each region. Comorbidities were also likely confounders, which were not fully assessed in this analysis.

Conclusion {#s5}
==========

Since the introduction of NOACs, newly diagnosed at-risk patients with AF are more often receiving guideline-recommended therapy, driven by increased use of NOACs and less treatment with AP and VKA therapies.

###### Key messages

What is already known on this subject?
--------------------------------------

-   Atrial fibrillation (AF) is associated with a fivefold increase in stroke risk. Anticoagulant (AC) therapy is known to reduce this risk in patients with AF, but evidence shows that it is underutilised.

What might this study add?
--------------------------

-   In this large, global, observational study of patients with newly diagnosed non-valvular AF and ≥1 additional risk factor for stroke, we investigated prospectively the changing pattern of antithrombotic therapy over the past 5 years, before and after the introduction of non-vitamin K antagonist oral ACs (NOACs). Since the introduction of NOACs, there has been an increase in newly diagnosed patients with AF at risk of stroke receiving guideline-recommended therapy, predominantly driven by increased use of NOACs and reduced use of vitamin K antagonists±antiplatelet therapy or antiplatelet therapy alone.

How might this impact on clinical practice?
-------------------------------------------

-   The acceptance of AC therapy in AF among physicians is a positive step. However, there has been no change in the proportion of patients that receive no antithrombotic treatment, including apparently eligible patients at high stroke risk and low bleeding risk.
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